Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Virtual

Jan 26, 2021 9:45 AM - Jan 28, 2021 5:00 PM

(US Eastern Standard Time)

Pharmacovigilance and Risk Management Strategies Conference

Session 2: Design and Conduct of COVID-19 Protocols – Implications for Efficacy and Safety

Session Chair(s)

Stephen  Knowles, MD, MRCP

Stephen Knowles, MD, MRCP

Chief Medical Officer

Halozyme Therapeutics, United States

The COVID-19 global pandemic has necessitated the rapid development, approval and conduct of clinical trials in order to address the urgent public health need for therapeutics and vaccines. The speed at which these programs has progressed is unprecedented. In this session, we will discuss the safety monitoring and safety endpoints in the trials; efficacy endpoints, including details of interim analyses; safety signal detection and risk management activities; Considerations for trial management between EUA/conditional marketing authorization and full approval and the role of the DSMB.

Learning Objective : At the conclusion of this session, participants should be able to:
  • Understand the design of clinical trials to answer the urgent questions of COVID-19 therapeutics and vaccines
  • Understand the safety monitoring required for rapidly moving programs
  • Understand the implications of early authorizations on ongoing studies and safety monitoring

Speaker(s)

Larry  Smith, PhD

SARS-CoV-2: From Pandemic Outbreak to Vaccine in 2020

Larry Smith, PhD

Consultant: COVID-19 Countermeasures, United States

Consultant

Peter W. Marks, MD, PhD

COVID-19 Vaccine Development

Peter W. Marks, MD, PhD

FDA, United States

Director, Center for Biologics Evaluation and Research

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.